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Abstract
Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by
a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The
prevalence in the general population is approximately 30/100,000. The median age at diagnosis is
65 to 70 years, but the disease may occur at any age. The female to male ratio is about 2:1. The
clinical picture is dominated by a predisposition to vascular occlusive events (involving the
cerebrovascular, coronary and peripheral circulation) and hemorrhages. Some patients with ET are
asymptomatic, others may experience vasomotor (headaches, visual disturbances, lightheadedness,
atypical chest pain, distal paresthesias, erythromelalgia), thrombotic, or hemorrhagic disturbances.
Arterial and venous thromboses, as well as platelet-mediated transient occlusions of the
microcirculation and bleeding, represent the main risks for ET patients. Thromboses of large
arteries represent a major cause of mortality associated with ET or can induce severe neurological,
cardiac or peripheral artery manifestations. Acute leukemia or myelodysplasia represent only rare
and frequently later-onset events. The molecular pathogenesis of ET, which leads to the
overproduction of mature blood cells, is similar to that found in other clonal MPDs such as chronic
myeloid leukemia, polycythemia vera and myelofibrosis with myeloid metaplasia of the spleen.
Polycythemia vera, myelofibrosis with myeloid metaplasia of the spleen and ET are generally
associated under the common denomination of Philadelphia (Ph)-negative MPDs. Despite the
recent identification of the JAK2 V617F mutation in a subset of patients with Ph-negative MPDs, the
detailed pathogenetic mechanism is still a matter of discussion. Therapeutic interventions in ET are
limited to decisions concerning the introduction of anti-aggregation therapy and/or starting platelet
cytoreduction. The therapeutic value of hydroxycarbamide and aspirin in high risk patients has been
supported by controlled studies. Avoiding thromboreduction or opting for anagrelide to postpone
the long-term side effects of hydrocarbamide in young or low risk patients represent alternative
options. Life expectancy is almost normal and similar to that of a healthy population matched by
age and sex.
Disease name and synonyms
Essential thrombocythemia (ET)
Primary thrombocythemia (PT)
Hemorrhagic thrombocythemia
Definition
Essential thrombocythemia (ET) is an acquired Myelopro-
liferative disorder (MPD) characterized by a sustained ele-
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vation of the platelet number with a tendency to
thrombosis and hemorrhage. Elevated platelet count is
related to an expansion of megakaryocytic lineage and the
disorder is usually considered to be a clonal disease aris-
ing in a multipotent stem cell.
Etiology
ET shares a molecular pathogenesis leading to overpro-
duction of mature blood cells with other clonal MPDs
such as Chronic myeloid leukemia (CML), Polycythemia
vera (PV), Myelofibrosis with myeloid metaplasia of the
spleen (IMF). CML is now easily recognized by the pres-
ence of the Philadelphia (Ph)-positive chromosomal
abnormality and/or the evidence of a specific molecular
marker, the disrupted protein kinase BCR/ABL. However,
despite the recent description of the JAK2 V617F mutation
in a subset of patients with PV, ET and IMF, the intimate
mechanism underlying molecular pathogenesis of these
myeloproliferative disorders is still a matter of discussion.
They are therefore generally associated under the com-
mon denomination of Ph-negative MPDs. The presence of
the mutation confers a proliferative and survival advan-
tage by rendering the cells more sensitive to incoming
stimulatory signals, causing clonal expansion of hemat-
opoietic progenitors in myeloproliferative disorders [1].
Epidemiology
The reported annual incidence rates for ET range from
0.59 to 2.53/100,000 (<9/100,000) inhabitants. A popu-
lation based survey in the city of Göteborg, Sweden,
adjusted to standard population reported an incidence
rate of 1.55/100,000, just under the incidence rate evalu-
ated in the same conditions for PV (1.97/100,000). The
prevalence is around 30/100,000 inhabitants [2]. The
diagnosis of ET is more frequently established today than
in the past [2,3], the most likely explanation being a wider
use of automatic count in routine examination leading to
the diagnosis of more non symptomatic ET patients. The
median age at diagnosis is 65 to 70 years but the range in
age of onset is characteristically wide. ET is often diag-
nosed during the third or fourth decade of life. Since the
diagnosis of ET is frequently recognized early in life and
the incidence of the disease is around two times higher in
females compared to males, the occurrence of ET associ-
ated pregnancies is common [4-6].
Clinical description
The clinical presentation of ET is dominated by a predis-
position to vascular occlusive events and hemorrhages.
Vascular occlusive events
Vascular occlusive events include major thrombotic
events involving the cerebrovascular, coronary and
peripheral arterial circulation. Thromboses of large arter-
ies represent a major cause of mortality associated with
the disease or can induce severe neurological, cardiac or
peripheral arteries disabilities.
Deep vein thrombosis also represents a potentially serious
and eventually life-threatening event due to the risk of
pulmonary embolism or related to the region involved as
it is the case in hepatic (Budd Chiari syndrome) or portal
thrombosis [7].
Vascular occlusive events can also occur in the micro-ves-
sels where they cause a wide range of clinical symptoms,
secondary to a transitory suspension of the circulation.
They are caused by platelet-mediated transient occlusive
thrombosis in the end-arterial circulation [8]. Aspirin-sen-
sitive erythromelalgia, one of the most characteristic
microvascular disturbances in ET, is described as burning
painful and ulcerative toes. It is often accompanied by a
warm, red or violet colored congested limb extremity. The
ischemic attacks of digital arteries may subsequently
progress towards small zones of limited necrosis or even
peripheral gangrene with palpable arterial pulsations.
Headaches are the most common neurological manifesta-
tions. Their pathophysiology remains uncertain. Some of
them resemble migraines. Sometimes, neurological symp-
toms in ET show a striking similarity with migraine aura
or accompaniments. In contrast, transient typical or atyp-
ical ischemic attacks, convulsions and sudden transitory
absences seem to result from an ischemic mechanism. Vis-
ual dysfunction manifests as attacks of diplopia and sud-
den reversible attacks of blurred vision. All these
symptoms share a specific reversibility or at least sensitiv-
ity to anti-aggregating agents and occur, at least in
younger ET patients, in the absence of conspicuous
atheromatous lesions in the arterial system.
Hemorrhagic manifestations
Bleeding in ET is often limited to recurrent skin manifes-
tations: bruising, subcutaneous hematomas, ecchymoses,
and epistaxis or gum bleeding. Petechiae are never seen. A
history of gastrointestinal blood loss (melena and/or
hematemesis) or biological evidence in favor of chronic
occult blood loss may be evidenced at diagnosis. Second-
ary bleeding, eventually life-threatening can also occur
after trauma or surgery. Hemorrhagic complications are
rarely observed during the course of the disease when
appropriate preventive measures are taken. Bleeding
symptoms are primarily observed in patients with the
highest platelet counts [9]. The bleeding diathesis is not
due to impaired platelet function but rather to an
acquired Von Willebrand's disease caused by proteolytic
reduction of Von Willebrand Factor (VWF) multimers.
There is an inverse relationship between VWF levels and
platelet counts. The VWF large multimer deficiency
appears at platelet counts of 1000 to 1500 × 109/L andOrphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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increases thereafter. Aspirin may unmask a latent bleeding
diathesis and may result in severe hemorrhagic complica-
tions. It is therefore contraindicated in patients with
bleeding history and a very high platelet count (in excess
of 1500 × 109/L leading to the acquisition of Von Wille-
brand's deficiency). If indicated, aspirin should be used in
the widely accepted low dose regimen (100 mg daily).
Asymptomatic presentation
The frequency of thrombohemorrhagic complications at
presentation of ET varies widely in the different retrospec-
tive studies. In a group of 809 ET patients diagnosed
according to the Polycythemia Vera Study Group (PVSG)
criteria from 11 retrospective clinical studies [10], the inci-
dence of thromboembolic events without bleeding was
42%, bleeding symptoms without thrombosis occurred in
1.4%, and both bleeding and thrombosis in 15% of the
patients. The arterial thrombotic manifestations were
described as microcirculatory disturbances in 41%. How-
ever, the most important message of this retrospective
compilation was that 36% of ET patients were free of
symptoms at diagnosis [11]. It is also important to note
that many of them remained free of complications during
the evolution of ET.
Maternal and fetal risk in pregnancy with ET
Maternal risk is limited. The increased risk of thrombosis
(present in healthy pregnant women as well) may be
worsened by ET. Hemorrhagic risk is low, except in
patients with acquired Von Willebrand's disease [4]. The
fetus seems to be at greater risks. There is an overall
increased incidence of first trimester miscarriage in one
out of three pregnancies. Late pregnancy loss is far more
frequently observed in ET than in normal population (5–
9.6% vs. 0.5%). An increased incidence of intrauterine
growth retardation (4–5.1%), preterm delivery (5.6–8%)
and placental abruption (2.8%) was reported. Placental
micro-infarctions due to increased platelet number and to
platelet activation seem to be the underlying pathological
basis of adverse events for the fetus. Overall live birth rate
may be as low as 50 to 57% [5]. A spontaneous decrease
in the number of platelets is frequently observed, begin-
ning after the first trimester of pregnancy.
Diagnostic criteria
Due to the lack of a specific molecular marker, the diagno-
sis of ET can only be settled after a step-by-step elimina-
tion of the other clinical situations associated with a
protracted elevation of the platelet number. The criteria of
this stepwise elimination were initially proposed by the
PVSG [12]. More recently, the World Health Organisation
(WHO) has proposed an improved new set of criteria
where specific abnormalities of megacaryocytopoiesis
associated with other bone marrow biopsy findings were
proposed as a common positive marker of Ph-negative
MPDs [13]. The JAK2 V617F mutation clearly represents a
new molecular marker for the Ph-negative patients. Ini-
tially described in PV patients, where it has been observed
in 65% to 97% of the cases [1,14-17], this mutation has
also been detected in subsets of each of the other Ph-neg-
ative MPDs: in 23 to 57% of ET and 43 to 67% of IMF
patients, as well as in some Ph-negative CML and MDS
[18,19]. The presence or absence of the V617F mutation
does not strictly correlate with any phenotype of Ph-nega-
tive MPD recognized according to either the PVSG criteria
or the WHO classification. As the absence of the mutation
has been repeatedly confirmed in more than 50% of ET
patients, the diagnosis of ET presently remains a mixture
of: 1) positive non specific arguments in favor of a Ph-neg-
ative MPD, including the JAK2 mutation and the bone
marrow (BM) biopsy findings and 2) elimination of PV
and IMF according to their currently used and phenotypi-
cally based definitions [12,13,20].
Arguments supporting the diagnosis of Ph-negative MPD
￿ Standardized histological BM features have been intro-
duced in the WHO diagnostic criteria for Ph-negative
MPDs. The diagnostic target of histopathology in patients
presenting an elevated platelet count according to this
classification may be twofold:
1) To confirm the presence of a Ph-negative MPD and
exclude long lasting reactive thrombocytoses (Rth).
This step can be achieved through a systematic analysis of:
a) megacaryocytopoiesis, focusing especially on the pro-
portion of giant vs. small forms, nuclear lobulation, mat-
uration defects, cluster formation by megacaryocytes; b)
BM cellularity; c) degree of expansion and of left shifting
of granulocyte and erythrocyte lineages; d) densification
of the reticulin network and presence of collagen fibrosis
in the BM stroma [7,21,22].
2) To offer a specific morphologic description of each
of the Ph-negative MPDs. For instance in ET, megakaryo-
cytopoiesis is characterized by the presence of large to
giant cells with a predominance of hyperlobulated stag-
horn nuclei loosely clustered throughout the BM. Cellu-
larity in ET is not significantly increased compared with
age-matched normal samples, and neutrophil granulo-
poiesis and erythropoiesis display no significant change
in the distribution and proliferation of both cell lineages.
In true ET there is no collagen fibrosis and no increase in
reticulin fibers of the myeloid stroma [22].
The relevant parameters in BM introduced by the WHO
classification to eliminate not only classical forms of PV or
IMF but mainly prefibrotic early stages of IMF or/and early
or latent PV will be described conjointly with the differen-
tial diagnosis of the other Ph-negative MPDs.Orphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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￿ The unique, acquired, clonal, somatic mutation of JAK2
occurring at the level of hematopoietic stem cell in a large
proportion of PV patients and in a lower subset of IMF
and ET patients has provided a completely new approach
to demonstrate a clonal origin of the cell proliferation, in
patients with a protracted platelet number. This new
marker unequivocally represents a major improvement
upon the previous cytogenetic studies, which were able to
demonstrate clonal cytogenetic abnormalities in BM cells
in less than 5% of ET patients. Interestingly, results of the
direct assessment of a clonal expansion in peripheral
blood cell of female ET patients with heterozygoty for X-
linked genes do not strictly match the presence of the
mutation. The unexpected presence of the mutation in
female ET patients with non clonal hematopoiesis,
according to X-linked gene studies, may only reflect a
lower sensitivity of methods based on quantification of X-
linked gene alleles compared to the polymerase chain
reaction (PCR) detection of the JAK2 mutation. Absence
of the V617F mutation in ET with unquestionable clonal
hematopoiesis may however suggest, on the contrary, that
other mutation(s) might still explain myeloid expansion
in these patients [23-28].
￿ Prior to the description of the JAK2 V617F mutation, a
set of positive markers including 1) "spontaneous"
growth of erythrocyte precursors (EEC) in absence of
added erythropoietin (EPO) [29]; 2) endogenous meg-
akaryocytic colony formation [30]; 3) decreased expres-
sion of c-MPL at platelet or megakaryocyte cell surface; 4)
polycythemia rubra vera protein 1 (PRV-1) and 5) nuclear
factor erythroid 2 (NF-E2) mRNA over expression in pol-
ymorphonuclear cells were initially described in PV
patients. However, like the JAK2 mutation, these markers
were also observed in subsets of other Ph-negative MPDs,
including ET. It was therefore suggested that these biolog-
ical markers may be used as criteria in favor of a clonal ori-
gin for the increased platelet number observed in a given
patient [31-35]. There is no longer an indication for these
investigations in patients positive for the JAK2  V617F
mutation, since it has been demonstrated that this muta-
tion induces activation of the JAK2 kinase directly
involved in the intracellular signaling, following the expo-
sure to EPO or thrombopoietin (TPO), in the elevated
expression of mRNA for PRV-1 or NF-E2 in granulocytes,
or in processes involving MPL maturation and trafficking.
However, since the mutation was still not found in some
patients who were shown to form EEC [36] and over
express PRV-1 [37], testing erythrocyte or megakaryocyte
colony formation may represent a non specific alternative
to BM biopsy to bring arguments in favor of an MPD in ET
and PV patients without JAK2 mutation.
￿ The presence of decreased circulating EPO levels that is
common to PV patients and to a subset of ET patients [38]
may also be used as an argument in favor of a MPD-
related origin of the elevated platelet number. However,
since a strong correlation between low EPO levels and the
diagnosis of PV has been demonstrated, there is a contro-
versy over using this criterion either as a biological marker
common to several kinds of MPD or as a strong indicator
of PV phenotype [39,40].
Diagnostic methods and differential diagnosis
Platelet number
The platelet number required for considering the presence
of ET has decreased since the initial definition of the dis-
ease, where it was initially fixed to over 1000 × 109 plate-
lets/L (Figure 1). In the last version of the PVSG criteria, it
has subsequently been lowered to over 600 × 109 plate-
lets/L observed on two occasions, separated by at least one
month (to eliminate a cause of transitory elevation of the
platelet number). The availability of positive arguments in
favor of a Ph-negative MPD-like bone marrow biopsy
findings and, moreover, evidence of the V617F mutation
makes it now possible to advocate this diagnosis with a
platelet number just over 450 × 109/L, whenever a sugges-
tive clinical context including erythromelalgia or occur-
rence of arterial or venous thrombosis [7,41] is associated.
Elimination of the causes of secondary thrombocytoses
The main causes of secondary thrombocytoses including:
iron deficiency, malignancy, chronic inflammatory dis-
ease, or histories of splenectomy or of protracted marrow
regeneration have to be excluded.
Elimination of iron deficiency includes a normal or
increased serum ferritin level in the absence of inflamma-
tory indices (erythrocyte sedimentation rate, fibrinogen,
C-reactive protein (CRP)) and normal red cell mean cor-
puscular volume. This step remains an important one in
the diagnosis of ET, both to exclude thrombocytoses
related to body iron stock depletion and to recognize PV
Diagnostic algorithm of thrombocytoses associated with Phil- adelphia (Ph) negative MPDs (Myeloproliferative disorders) Figure 1
Diagnostic algorithm of thrombocytoses associated with Phil-
adelphia (Ph) negative MPDs (Myeloproliferative disorders).Orphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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masked by iron deficiency. The original requirement for
stainable marrow iron is for this reason still proposed in
one of the most recent set of criteria [36]. If these measure-
ments suggest iron deficiency, a closely monitored trial of
iron therapy may be necessary to eliminate progression of
hematocrit toward the polycythemic range. Again, the
availability of positive arguments in favor of a Ph-negative
MPD such as BM biopsy findings and, moreover, evidence
of the V617F mutation, represent definitive arguments
against secondary thrombocytoses (RhT), although these
investigations might be required only during later steps of
investigation of patients with protracted thrombocytoses.
Elimination of familial hereditary thrombocytoses
TPO  gene mutations, causing elevated TPO levels and
therefore leading to familial thrombocytosis, have been
described [42]. The context of several cases of thrombocy-
toses observed in the same offspring or increased TPO lev-
els in sporadic ET may prompt a check for a gain of
function mutation of the TPO gene. This eventuality is dif-
ferent from situations where several cases of true MPDs
are aggregated in the same family [43] suggesting the pres-
ence of a predisposition factor to PV, ET, IMF and CML. In
these cases, additional events such as chromosome trans-
location (9;22) (q34;q11) in CML or several somatic
mutations arising in hematopoietic stem cell (including
the V617F mutation) may usually be responsible for the
disease onset or for the specific characteristics of prolifer-
ation leading to the phenotypic classification of the final
MPD.
Elimination of primary thrombocytoses associated with chronic 
myelodysplastic syndromes (MDS)
This step was proposed [12,13] to exclude patients whose
hemograms, myelograms or cytogenetic abnormalities
were suggestive of myelodysplasia. The presence of the
JAK2 mutation in some patients with MDS and siderob-
lastic anemia [18,19] may justify the individualization in
the most recent classification of myeloid neoplasia of a
distinct myeloproliferative-myelodysplastic overlap cate-
gory [44]. However, the distinction of these borderline sit-
uations from a "true ET" might still be maintained, at least
in studies in which long term evolution or evaluation of
treatment are concerned.
Elimination of primary thrombocytoses associated with the full-blown 
picture or with more subtle presentations of a chronic 
myeloproliferative syndrome different from ET
1) The elimination of the more or less pure thrombo-
cythemic forms of CML [45] that previously led to the
concept of Ph-negative MPD, is now easily achieved and
based mainly on the determination of the presence of
BCR/ABL transcripts in peripheral blood, rather than on
the research of chromosome Philadelphia in BM cells.
Distinction between ET and PV patient
2) The identification of features specific to ET among
patients with a primary Ph-negative MPD and an
increased platelet number is more controversial. Determi-
nation of the total red cell volume (TRCV) in all patients
with thrombocytoses and hemoglobin (Hb) or hemat-
ocrit (Ht) values equal or superior to normal value using
a radioisotopic method [46], after exclusion or treatment
of iron deficiency was recommended in the PVSG and
WHO criteria for ET. Patients with TRCV>125% of normal
value definitively represent PV patients with an increased
platelet count (Figure 2). However, there is an unequal
availability of the opportunity of TRCV measurement
according to the geographical repartition of centers
involved in MPD evaluations. The fact that this isotopic
measurement is costly, time consuming and non specific
(since, alone, it does not differentiate an increased red cell
volume in congenital polycythemia (CP), secondary
erythrocytosis (SE) or PV) has prompted several alterna-
tive strategies for differentiation between PV and ET. None
of them can presently be regarded as universally accepted.
￿ Spontaneous EEC and a low serum EPO level are criteria
of high specificity but low exhaustively for the diagnosis
of PV. EEC assays are almost always negative in RhT and
positive EEC results have been extensively reported in ET
patients [40]. The presence of EEC has even been recom-
mended as a minor criterion for the diagnosis of ET. Fifty
percent of patients with ET diagnosed according to the
PVSG criteria have EPO-independent EEC and a variable
proportion of them have low serum EPO levels reflecting
a biologically distinct subgroup of ET at risk of progres-
sion to PV [35,39].
￿ Standardized histological BM features (introduced in
the WHO diagnostic criteria for Ph-negative MPDs) have
been proposed to distinguish initial stages of PV without
an obvious increase in Ht level but with an elevated plate-
Diagnostic algorithm of Essential thrombocythemia (ET) Figure 2
Diagnostic algorithm of Essential thrombocythemia (ET).Orphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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let count, mimicking ET on the basis of an increased BM
cellularity, an increased and left shifting pattern of both
erythropoiesis and granulopoiesis. Megakaryocytes vary
in size, generating a pleiomorphic aspect without matura-
tion defects but with a more pronounced tendency toward
clustering than in "true" ET.
￿ Evidence of the JAK2 V617F mutation (found in 90% of
PV patients) has been proposed as a prerequisite criterion
for the diagnosis of PV [36] but it may be of no help for
differentiation of 50% of ET patients positive for JAK2
mutation. However, it is worth noting that differences in
the phenotype presentation and clinical events between
the JAK2 positive and JAK2 negative ET patients have been
demonstrated [47], even if these differences are mainly
statistically based and remain small. Furthermore, the
presence of EEC and low serum EPO level are still
observed in patients that do not carry JAK2  mutation
[1,8]. Therefore, disease classification as well as patient
management according to the JAK2 status seems to be pre-
mature.
Distinction between ET and IMF patients
Patients with a full-blown picture of IMF including large
spleen, tear drop shaped red cells, leukoerythroblastic
blood picture and collagen fibrosis on BM biopsy are eas-
ily eliminated.
￿ The recognition of patients presenting an increased
platelet number that may correspond to a prefibrotic
phase of a Ph-negative MPD was one of the first evidences
demonstrating the heterogeneity of ET defined according
to the PVSG criteria. The identification of these patients is
based on BM morphology according to the WHO criteria
[20,48] and is associated with a significant loss of life
expectancy when their evolution was compared to
patients with BM feature specific of ET. Discrimination of
prefibrotic or early fibrotic stages of IMF, or IMF-0 and
IMF-1 respectively (as it has been proposed to name
them) is based on an age-matched increase in marrow cel-
lularity, clustering of megakaryocytes exhibiting dense
hyperchromatic cloud-like nuclei and deviation of
nuclear cytoplasmic maturation. This stage of prefibrotic
Ph-negative MPD is characterized by a pronounced prolif-
eration and left-shifting of the neutrophil granulopoiesis
but is devoid of collagen fibrosis and even of an increase
in reticulin fibers (at least in IMF-0).
￿ The JAK2 V617F mutation found in 43 to 67% of classi-
cal IMF patients is more frequently homozygous (6 to
18%) compared to ET (3 to 4%). Homozygoty for JAK2
mutation associated with a loss of heterozygoty on chro-
mosome 9p is even more frequent in PV (24 to 27%) and,
moreover, almost always present when PV has progressed
to myelofibrosis [1,49]. In prefibrotic or early fibrotic
patients (IMF-0 or IMF-1), no difference in the frequency
of JAK2 mutation has presently been observed [47]. No
data on the predictive value of the sequential evaluation
of circulating CD34 cells are presently available for detec-
tion of this subset of patients whose recognition remains
exclusively based on BM biopsy examination.
Management including treatment
Risk categories of patients with ET
Most of the published treatment algorithms [36,50-55]
rely on the concept of a risk stratified management. The
majority of them distinguished three risk categories based
mainly on the estimation of the thrombohemorrhagic
risk. This limited ambition is due to the fact that at present
there is no drug known to cure the underlying disease or
to prevent the risk of clonal evolution. The current ration-
ale for using drugs is therefore either to prevent, or more
rarely, to treat a thrombohemorrhagic event.
High risk patients
The criteria recognized as major risk of thrombosis and
embolism by almost all investigators [50,51,53,55] are:
￿ Age: the risk increases significantly in patients older than
60 years.
￿ Previous thrombotic event.
When the stratification also includes an evaluation of the
risk of major hemorrhage [50,51,55], the most frequently
considered factors are:
￿ Platelet count >1500 × 109/L.
￿ History of major bleeding or, as learned from The Euro-
pean Collaboration on Low-dose aspirin in Polycythemia
Vera (ECLAP) experience, a history of minor bleeding
with a platelet count >1000 × 109/L, especially in patients
with a long disease duration >15 years) [56].
Low risk patients
The most restrictive definition of patients at low risk
includes:
￿ Patients aged less than 40 years.
￿ Patients presenting with no high risk feature.
￿ Patient without cardiovascular risk factor and throm-
bophilia of clinically significant familial expression.
Intermediate risk patient
Intermediate risk patients represent a category without a
clear consensus on its definition. The risk of thrombosis is
often regarded as intermediate according to:Orphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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￿ Age (patients aged between 40 and 60 years).
￿ Well established risk factors of cardiovascular disease
(hypertension, diabetes, smoking and hypercholestero-
lemia). In the Medical Research Council (MRC) PT1 study
the presence of these factors was even sufficient to include
patients in the high risk group.
￿ An intermediate risk related to a platelet count between
1000 and 1500 × 109/L has also been proposed [50,56].
In this case, the platelet number was regarded as increas-
ing the thrombotic risk when associated with a vascular
risk factor or familial thrombophilia [50], and the hemor-
rhagic risk when associated to either minor bleeding or
long term duration of the disease [56].
Therapeutic intervention in ET patients
To reduce the vascular risk in ET patients (except for the
management of reversible cardiovascular risk factors) the
therapeutic intervention is limited to the decision of
decreasing the platelet count or altering the platelet func-
tion by aspirin or an equivalent therapy.
Therapeutic options
As a first step in their management, patients should have
an assessment of their risk factors for vascular disease and,
if necessary, modulation of hypertension, hyperlipemia,
smoking habits and overweight.
A. Anti-platelet treatment
Aspirin (and alternative anti-platelet agents)
Aspirin (Asp) is the standard therapy for ischemic mani-
festations of the microcirculation. Reducing the number
of platelets also attenuates the symptoms. Continuous
Asp therapy is indicated when the occlusive manifesta-
tions of the microcirculation persist despite lowering the
number of platelets.
The role of Asp in the prevention of arterial thromboses
has been clearly established in the general population.
The benefit of a low dose Asp in preventing the risk of
thrombotic complications without increasing signifi-
cantly the hemorrhagic risk in PV patients has recently
been demonstrated in the extensive prospective ECLAP
study [57]. A preliminary pilot study in polycythemia
patients receiving either 40 mg/day of Asp or a placebo
showed that this dosage fully inhibited the cyclooxygen-
ase activity and did not cause any major hemorrhage [58].
Anti-platelet therapy has not yet prospectively been
shown to reduce the incidence of thrombosis in ET, how-
ever, the combination of an anti-aggregating agent with
cytoreductive therapy has been found to be safe and to
reduce the incidence of thrombosis in ET patients in retro-
spective studies [59,60]. Low dose Asp is often prescribed
as soon as an excess of platelets is discovered by the gen-
eral practitioners, however, objective data in favor of the
preventive role of Asp against the vascular risk in symp-
tom-free patients not taking a platelet-lowering treatment
are not presently available and the use of Asp is contrain-
dicated in ET patients with extreme thrombocytosis in
whom the presence of Acquired Von Willebrand syn-
drome might be screened.
ADP receptor antagonists (thienopyridines such as ticlopi-
dine and clopidrogel) have a growing role in patients with
ongoing thrombotic events (suggesting resistance to Asp).
At present, there are no data to recommend their use in
MPD patients [61].
B. Platelet-lowering treatment
Hydroxyurea (HU) has emerged as the reference platelet-
lowering agent in high risk ET patients. A valuable platelet
lowering as well as anti thrombotic activity has been dem-
onstrated in both of the (only) two published rand-
omized prospective trials concerning the treatment of this
category of patients [62,63]. However, the still ongoing
controversy (according to whether or not HU is leuke-
mogenic) has prompted the consideration of two main
alternative drugs: anagrelide, now authorized for market-
ing in European countries, and interferon α (IFN-α). Two
more medications, pipobroman (available only in certain
European countries) and busulfan are also used as plate-
let-lowering drugs in ET patients, as well as platelet apher-
esis, which may be the preferred therapeutic option in
case of emergency.
Hydroxyurea (Hydroxycarbamide, HU)
Efficacy
The efficiency of HU in controlling the platelet number in
high risk ET patients has been further documented by the
recently published results of the MRC PT1 trial [63]. A lack
of platelet control was observed in less than 4% (15
patients) of the 404 patients treated by HU. At 3 months
90% of the patients had a platelet number <600 × 109/L.
The median platelet count at 6 months was <400 × 109/L.
Stable reduction of the median platelet number (lower or
equal to 400 × 109/L) was obtained with HU for the fol-
lowing 24 months. Importantly, the protection from
thrombosis in high risk ET patients already demonstrated
by Cortellazzo et al. with HU (plus anti-aggregating agents
in almost 70% of the patients) [62] was confirmed by this
study with HU associated with Asp in all the patients.
After 2 years, the prevalence of thrombotic events was 4%,
identical to the former study of Cortelazzo, and signifi-
cantly lower than the prevalence of 24% found in the con-
trol group [62].
Side effects
Clinical and hematological tolerance of HU is usually
good even during very long periods of time. Major shortOrphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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term toxic effects are dose limiting hematological impair-
ment and fever. However, oral and leg ulcers and other
skin lesions are currently observed but often only after
several months or years of treatment, suggesting the role
in their occurrence of the cumulative dose received.
Mutagenic potential and long term resistance
HU was initially introduced in the treatment of ET
patients because it is supposedly non mutagenic. Its
mechanism of action is the inhibition of DNA synthesis
by blocking the ribonucleoside reductase activity. As
leukemogenic effects of HU have not been definitively
eliminated, this molecule should be used cautiously in
young individuals. After a continuous use in ET patients,
the non selective effect of the drug on platelet reduction
may, in the long run decrease, lead to anemia and neutro-
penia after dosage escalation of HU. This delayed hemato-
logical toxicity (leading to a withdrawal of the drug)
sometimes seems to be related to a progression of the dis-
ease.
A unified definition of the clinical resistance and intoler-
ance to HU in ET is proposed [64] and includes:
1. A platelet count persistently high (>600 × 109/L) after 3
months of treatment by HU at maximum daily possible
dosage.
2. Or at any dose of HU: a) A decrease of the white blood
cell (WBC) counts under 2.5 × 103/mm3 or of Hb level
under 10 g/dl to maintain the platelet number under 400
× 109/L; b) Presence of leg ulcers or other unacceptable
muco-cutaneous manifestations; c) Presence of HU
related fever. In these situations the risk of leukemic pro-
gression in patients requiring treatment by multiple
agents should not be underestimated and has implica-
tions for the choice of a second agent [51].
The status of ET patients according to the JAK2 V617F
mutation might affect the response to HU treatment. A
recent study of 640 high risk patients (MRC PT1 trial,
JAK2 genotype data available) has demonstrated that HU-
treated patients positive for the JAK2 mutation had a per-
sistently lower platelet count than the individuals nega-
tive for the JAK2  mutation. Furthermore, ET patients
positive for the JAK2 mutation were more sensitive to HU
than ET patients without this mutation, as demonstrated
by lower doses HU required to control their platelet count
and higher decrease in their Hb concentration and WBC
counts compared to the pre-treatment levels. These differ-
ences in treatment sensitivity according to the mutation
status of high risk ET patient was not seen in the group
treated with anagrelide (see below) [47].
Anagrelide
Anagrelide (Ana) is an oral imidazoquinazolin com-
pound initially developed for its potent inhibition of
platelet aggregation. It causes thrombocytopenia at doses
below those exhibiting an anti-aggregating effect.
Efficacy
In the largest study to date, the efficacy of anagrelide in
controlling the platelet count was evaluated and demon-
strated in 934 ET patients [65]. This was further docu-
mented in high risk ET patients by the recently published
results of the MRC PT1 trial [63]. In this prospective rand-
omized study, a lack of platelet control was observed in
less than 4% (19 patients) of the 405 patients treated by
anagrelide. At 3 months the 90th percentile of platelet
count was only <800 × 109/L. However, at 6 months the
median platelet count was <400 × 109/L and a stable
reduction of the median platelet number (lower or equal
to 400 × 109/L), similar to what was obtained with HU,
was maintained during the following 24 months. A mech-
anism involving a diminution of the size and ploidy of
BM megacaryocytes without modification of their number
is supposed at the origin of the platelet number reduction.
This may explain why anagrelide does not usually modify
the number of white cells or does not cause a significant
reduction of the Hb concentration.
The comparison of HU+Asp vs. Ana+Asp in this study
restricted to high risk patients [63] has demonstrated that
anagrelide and aspirin offer a confirmed protection from
thrombosis. The prevalence of thrombotic events for ana-
grelide-treated patients was 8% (significantly less than
24% in the control study arm, without cytoreduction of
the princeps control study of Cortelazzo et al.) [62]. How-
ever, in this trial (despite an equivalent control of the
platelet number) protection from thrombosis in patients
treated by Ana+Asp was less efficient than with HU+Asp
(prevalence of thrombotic events 4% at 2 years). Interest-
ingly, protection from arterial thrombosis and especially
AIT (transient ischemic attack) was better with HU+Asp;
high risk ET patients treated with Ana+Asp had a lower
rate of venous thromboembolism. In the same study but
in an article published later [47], it was observed that the
rates of arterial thrombosis in JAK2  V617F positive
patients randomized to anagrelide were higher than in
those randomized to HU, whereas equal numbers of arte-
rial thromboses were observed in the two arms of treat-
ment for the patients negative for JAK2 V617F mutation.
Side effects and mutagenic potential
To date, 2251 patients were evaluated for safety of anagre-
lide [65]. With a maximum follow-up of 7 years, leuke-
mogenic effect has not been demonstrated. Major side
effects of anagrelide are consistent with its mechanism of
action as a phosphodiesterase inhibitor [51] and includeOrphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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headache (12.6%), tachycardia-type palpitations
(15.5%), fluid retention (6%) and gastrointestinal intol-
erance (14%) leading to premature interruption of the
treatment in 22% of the patients [63]. A small number of
reversible cardiomyopathies have been described, suggest-
ing that an evaluation of cardiac function should be per-
formed in elderly patients with previous cardiac disorders
[53].
The comparative study of HU+Asp vs. Ana+Asp of the
MRC PT1 trial has shown that anagrelide was more poorly
tolerated than HU (frequency of side effects 21.7% vs.
10.6%). The drop-out rate has been estimated to around
14% [66]. There was more concern in this study from the
statement that major hemorrhages occurred more fre-
quently in the Ana+Asp arm than in the HU+Asp arm,
suggesting a potentiation of the anti-aggregating effects of
aspirin by its association with anagrelide. The question
raised by the difference in the rate of progression toward
myelofibrosis observed in the anagrelide arm (16 vs. 5
events) needs further evaluation. A previous study com-
paring BM biopsy findings before and after therapy failed
to demonstrate a progression in reticulin or collagen
fibrosis during the treatment with anagrelide [67]. Further
data may be expected from an on-going study comparing
anagrelide to HU in ET patients (newly diagnosed accord-
ing to the WHO criteria) in whom BM findings will be
submitted to a panel revaluation (Study by AOP pharma
007).
Anagrelide has been approved by Food and Drug Admin-
istration (FDA) and by European authorities as oral treat-
ment for ET and thrombocytoses associated with PV.
Nevertheless, its usage is recommended in case of failure
or intolerance to HU.
Interferon-α (IFN-α)
Efficacy
Efficiency of IFN-α administered by subcutaneous injec-
tions to reduce the platelet number has been documented
in a large number of cohort studies [50]. Only a prelimi-
nary report of a multi-center comparative (HU vs. IFN)
randomized trial has been published [68]. The overall
response rate was 84% and a complete normalization of
the platelet count was obtained in 53% of the patients
after 3 months. A positive effect on clinical symptoms was
associated with normalization of the platelet count; pre-
cise information about the reduction of the rate of throm-
botic events in high risk patients is not presently available
[69].
Side effects and mutagenic potential
No associated leukemogenic effect has been reported with
IFN-α. Side effects, mainly flu-like syndrome, are com-
mon at the initiation of IFN treatment. They can subside
thereafter, mainly when IFN doses are sharply lowered
during the subsequent maintenance therapy. However,
they lead to discontinuation of the drug in 16.5% of the
patients.
Interesting data from phase II studies of pegylated (Peg)
IFN-α are now available. The rate of subcutaneous injec-
tions, only once per week, improves the compliance to the
treatment and increases the number of long lasting hema-
tological responses [70]. A preferential targeting of the
JAK2  V617F mutated clone by Peg-IFN-α  has been
recently suggested by a phase II study in PV [71]. In this
prospective study of 27 PV patients positive for the JAK2
mutation, a high rate of complete hematological
responses was observed together with a decreased expres-
sion of mutated JAK2 in peripheral blood cells in 87% of
patients.
C. Alternative cytoreductive therapy
Pipobroman (PI)
Pipobroman (PI) is a piperazine derivative. PI appears to
competitively inhibit pyrimidines though it shows a struc-
tural resemblance to alkylating agents.
Efficacy
The efficacy of PI in controlling the platelet number in
patients with ET is close to that of HU, with an overall
response around 95%, documented in several cohort
studies [72-74]. In 118 ET patients at high risk for throm-
bosis treated by PI, protracted hematological remissions
and good clinical and hematological tolerances have been
reported after a long follow-up [74]. The cumulative risk
of thrombosis at year 10 was equal to 14%. Therefore,
although not demonstrated by prospective or compara-
tive studies, PI has presumably, like HU, a role in prevent-
ing thrombotic events in high risk patients.
Side effects and mutagenic potential
Treatment with either HU or PI was carried out on rand-
omized 292 patients with PV [75]. The risk of leukemia
was approximately 10% after13 years of follow-up, with
no significant difference between the two arms. Therefore,
a long term leukemogenic risk was suspected in PI-treated
PV patients, even if this treatment was given alone [75]. In
ET, however, the cumulative risk of acute leukemia was
3% at 10 years and 6% at 15 years [73]. A comparison,
although retrospective, between PI and HU has been
recently assessed. After a median follow-up of 104
months in a cohort study of 155 ET patients, a signifi-
cantly lower transformation rate was observed in PI-
treated patients [76].
Busulfan (BU)
Busulfan (BU) is an alkylating agent formerly used in the
treatment of chronic myelocytic leukemia. Despite theOrphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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reputation of this drug to induce severe and protracted
bone marrow aplasias in CML, BU is sometimes proposed
to control the platelet number in elderly patients with ET.
Rationale for this usage comes from the statement that it
is the only treatment able to induce sustained hematolog-
ical remissions without need of maintenance therapy.
Treatment algorithm
All patients
￿ Check and treat all the reversible cardiovascular risk fac-
tors (hypertension, hypercholesterolemia, diabetes, obes-
ity, smoking).
￿ Consensus to recommend either a systematic investiga-
tion of associated constitutional or acquired factors of
thrombophilia in patients without a clinically significant
familial history or to screen average ET patients for
Acquired Von Willebrand syndrome is lacking.
Hight risk patients
￿ Cytoreduction is recommended in high risk patients.
In the older patient group (>60) the recommended cytore-
ductive treatment is HU. In case of resistance or intoler-
ance to HU, consider only non-mutagenic alternative
drugs for second line treatment.
There is still reluctance in using HU in young patients.
High risk patients under 60 must be informed of the
potential side effects occurring after a protracted use of the
drug. Non-mutagenic alternative (anagrelide or IFN-α
may be considered, although antithrombotic effects of
these drugs are regarded presently either as inferior to HU
(in term of AIT or arterial thrombosis (for anagrelide) or
not yet evaluated (for IFN).
 The aims of cytoreduction are to bring the platelet
number into the normal range in patients with high risk
of thrombosis. In patients whose high risk is mainly hem-
orrhagic, lowering the absolute platelet number largely
under 1000 × 109/L may be the most important goal.
 Aspirin therapy is recommended in high risk patients
(except when contra-indicated by platelet count >1500 ×
109/L, history of major bleeding or presence of three
minor risk factors). The benefit of combining of anti-
aggregating agent with a cytoreductive therapy (although
not demonstrated in randomized studies in ET) is sup-
ported by the demonstration of antithrombotic effect of
this combination in PV patients and by the presumptive
thrombotic role of platelet activation.
Low risk patients
￿ Abstention of cytoreduction is recommended in low risk
patients. The risk of thrombosis in asymptomatic low risk
ET patients has been evaluated in several studies [77,78]
and may not be high enough to warrant the use of poten-
tially mutagenic or toxic cytoreductive therapy [36,50,53].
￿ Prescription of low dose aspirin is often proposed
[36,53] and may rely again on the presumptive role of
platelet activation in vascular risk.
Intermediate risk patients
￿ Consider cytoreduction in patients in the intermediate
age group (40–60), if associated risk factors are present
(uncontrolled cardiovascular risk factor, thrombophilia
of significant familial expression).
￿ Prescription of low dose aspirin is supported in this
group of patients by uncontrolled observational studies in
ET patients.
Management of ET in pregnancy
Information available in the medical literature for the
management of ET in pregnancy is still limited, but a large
number of pregnancies have been reported in retrospec-
tive studies [4-6]. Recommendations for management of
ET in pregnancy based on current knowledge have been
elaborated [5]. They include an evaluation of the maternal
risk of thrombosis and hemorrhages, based on the current
characteristics of the disease: previous venous or arterial
thrombosis and previous hemorrhages (during previous
pregnancies or not), as well as ET induced previous com-
plications: early (first trimester) or late (second or third
trimester) pregnancy loss, intrauterine death or still birth,
decreased birth weight (of more than 5th centile for gesta-
tion), severe pre-eclampsia, ante- or post-partum hemor-
rhage. Evaluation of the trend in the platelet number in
patients without current cytoreduction is mandatory. The
threshold for platelet reduction may be over 1500 × 109/
L rather than over 1000 × 109/L due to expected natural
decline of platelets after the first trimester of pregnancy. A
systematic biological screening for associated prothrom-
botic risk factors is not clearly indicated in patients with-
out personal or familial history of thromboses. Strong
coordination between the obstetrician (monitoring the
pregnancy) and the hematological department (managing
ET) is mandatory.
The therapeutic options include antithrombotic treatment
and cytoreductive agents. Low dose aspirin is safe during
pregnancy. However, demonstration of a significantly bet-
ter outcome of pregnancies evolving under continuous
aspirin treatment has not been confirmed by a recent
report [6]. Some studies have suggested that aspirin from
the onset of pregnancy plus heparin from the second tri-
mester might improve pregnancy outcome [79].Orphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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Many pregnancies in ET have a successful outcome with
minimal therapy. Cytoreductive treatment should prefer-
ably be avoided during pregnancy, especially during the
first trimester. None of the agents currently used for
cytoreduction in ET has a product license for use in preg-
nancy. As IFN-α does not cross the placental barrier, it is a
potential therapeutic solution when platelet reduction is
required for high risk ET pregnant patients. A small
number of publications is available, showing, up to now,
no toxicity for the fetus [5,80]. Breast feeding is however
not recommended during cytoreductive treatment includ-
ing IFN-α. Several retrospective analyses have also led
authors to suggest that reducing the platelet number using
IFN-α  for patients with prior pregnancy events might
improve the chance of a successful outcome in subse-
quent pregnancies.
When ET has been already diagnosed, some important
issues concerning the risk of pregnancy should be dis-
cussed before conception. For ET female already treated
with HU, a wash-out period of 3 months has been recom-
mended. However, for pregnancies where HU had been
used during a more or less limited period of time, the tox-
icity of the product is probably less than it might be antic-
ipated.
Anesthetists prefer aspirin to be stopped two weeks before
delivery, to prevent the risk of hematoma after epidural
and spinal anesthesia. Low molecular weight heparin
(LMWH) is given as an alternative to aspirin. The greatest
risk for thromboembolism is post partum and prophylaxis,
usually in the form of aspirin and LMWH, should be con-
tinued for several weeks.
Prognosis
No substantial differences between life expectancy of 247
patients with ET, according to the PVSG criteria and that
of a control population were found by Rozman et al.
[76,81]. Nevertheless, the common feeling that ET is a
rather benign MPD, affecting more the quality of life than
the overall life expectancy, has been challenged by recent
publications. An eventual loss of life expectancy may be
demonstrated if the group of observed patients is chosen
according to selective BM based criteria. Discrimination of
prefibrotic (IMF-0) or early fibrotic (IMF-1) stages of IMF
from true ET, according to WHO classification, demon-
strated a shortening of life expectancy of 32.3% and
21.6% for the first two subgroups compared to only 8.9%
for true ET patients [22]. Bazzan et al. compared a cohort
of 187 consecutive ET patients to age-matched healthy
people living in the same area during a follow-up period
of 15 years [82]. This study demonstrated a significantly
higher mortality rate and a lower thrombosis-free survival
in patients younger than 55 years. On the contrary, in a
group of 74 women with ET younger than 50 years at diag-
nosis, the overall survival was similar to that of an age-
and sex-matched control population, with a low inci-
dence of life-threatening thrombohemorrhagic complica-
tions or acute leukemia but an increased incidence of first
trimester miscarriages [83].
Due to the heterogeneity of the disease, suggested by these
prognostic discrepancies, efforts toward understanding
the risk of hemostatic complications in ET patients, as
well as the risk factors involved in the clonal progression
toward PV, IMF, myelodysplasia and acute leukemia have
been attempted for a long time.
Risk of thrombosis
The Cortelazzo study [84] in a cohort of 100 historical
patients with ET has shown that the overall risk of throm-
bosis was equal to 6.6 % patients/year compared to 1.2%
control individuals/year. Three important risk factors
were identified by this study. The risk of thrombosis
increases with age (1.7% patients/year before 40 years;
6.3% patients/year between 40 and 60; 15.1% patients/
year after 60 years). A previous history of vascular occlu-
sive episode increases the incidence of thrombosis from
3.4 to 31.4% patients/year. Patient's exposure time to ele-
vated platelet number was also, in this study, predictive
for the risk of thrombosis, however no document has ever
demonstrated proportionality between the thrombotic
risk and the degree of elevation of the platelet number.
Moreover, 10 to 20% of severe thrombotic complications
occur in ET patients with a platelet number under 600 to
700 × 109/L [85].
A second study by Cortelazzo et al. demonstrated that the
reduction of the platelet count by HU randomized against
abstention of cytoreductive treatment in a group of 114 ET
patients with an elevated risk for thrombosis (age over 60
or previous thrombotic event) resulted in a significant
prevention of thrombosis or severe ischemia (AIT) even in
the background of an anti-aggregation therapy adminis-
tered in nearly 70% of patients [62].
A number of other features have been claimed to correlate
with thrombotic complications in ET:
￿ The presence of thrombophilia: an increased risk of
venous thromboembolism has been associated with a car-
riership of factor V Leiden [86]; an increased prevalence of
antiphospholipid antibodies in ET patients has been also
noted [87].
￿ Cardiovascular risk factors such as hypertension, smok-
ing and hypercholesterolemia have been implicated in the
increased risk of thrombosis in ET patients, as shown by
retrospective studies [88-90].Orphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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￿ Presence of the JAK2 V617F clonal mutation and platelet
and granulocyte activation pattern are still subject to
investigations.
Clonal pattern of X chromosome inactivation [25-27],
reduced expression of MPL in BM megakaryocytes and
over expression of PRV1 mRNA in peripheral blood gran-
ulocytes [34,35] (previously proposed as criteria in favor
of the diagnosis of clonal MPDs) were all associated with
an increased risk of thrombosis. However, the role of the
clonal mutation of the JAK2 tyrosine kinase gene in the
risk of thrombosis is still controversial. The presence of
the mutation may increase the risk of arterial thrombosis
[91], may be associated with a global increase of vascular
complications [1] or may correlate, but not to a significant
level, to the elevated risk of venous thrombosis at diagno-
sis [47]. In another study, however, the JAK2 mutation sta-
tus had not been correlated to the occurrence of
thrombotic events [92].
The role of platelet hyperactivation [93] and granulocyte
activation pattern [94] in the risk of vasculo-occlusive epi-
sodes in ET patients have been previously suggested. In
more recent studies, a JAK2 gene dosage effect on granulo-
cyte activation pattern was demonstrated in MPDs [49]
along with, in ET, the activation of monocytes and platelet
being more frequently observed in patients with a history
of thrombosis [95]. In this last study, the JAK2 V617F
mutation was found associated with the increased platelet
activation. Clearly more information is needed regarding
gene mutations and peripheral cells activation and their
incidence on vasculo-occlusive complications.
Hemorrhagic risk
A risk of major hemorrhage of 0.33% patients/year during
follow-up has been deducted from 21 previously pub-
lished studies [50]. As already mentioned, severe hemor-
rhages were reported to be more common in patients with
platelet count >1500 × 109/L but the risk decreases when
platelet number is reduced by treatment, allowing the use
of low dose aspirin associated to cytoreduction in these
patients. In the ECLAP study of PV patients, a history of
previous bleeding problems was also an important predic-
tor of major hemorrhagia. Recently, a tentative categoriza-
tion of the hemorrhagic risk has been proposed [56]:
A) High: in patients with platelet number >1500 × 109/L
or history of major bleeding or presence of all three minor
risk factors. Minor risk factors proposed are: 1) Disease
duration over 15 years; 2) Platelet count >1000 × 109/L; 3)
History of minor bleeding.
B/Intermediate: when patients have two minor risk fac-
tors.
C/Low: in all the other cases.
Risk of a clonal progression of ET
• progression or transformation into PV
In ET patients, an increase of the Hb and Ht levels toward
values observed in patients with primary erythrocytosis,
or even a progression to a full-blown picture of PV
(according to the PVSG criteria) has been observed in up
to 5–6.5% of large series of patients [96]. A critical revue
of the criteria used at diagnosis to differentiate ET and PV
may probably explain some of these apparent early pro-
gressions. The presence of EEC in BM cells, an increase
level of PRV-1 mRNA in granulocytes and low circulating
EPO levels in ET patients has already been proposed as an
indication of a close relationship between PV and a subset
of ET patients [35,38]. More recently, in a large prospec-
tive study of 806 ET patients it has been observed that pro-
gression to PV was restricted to patients with the JAK2
V617F mutation [47]. In this study, statistically higher Hb
and circulating granulocytes levels, lower EPO values and
hypercellular BM on biopsy material in JAK2 V617F posi-
tive-compared to JAK2 negative ET patients, suggested a
continuum in mutated patients between ET and PV phe-
notypes. A statistically different rate of progression to a PV
phenotype in JAK2 mutated ET patients was also observed
in a retrospective study with a long term follow-up [92].
• progression into myelofibrosis
The risk of myelofibrotic transformation is shared by all
Ph-negative MPDs diagnosed according to the PVSG crite-
ria. Myelofibrosis itself is not a disease but rather a reac-
tion pattern of the BM to cytokines released from the
clonal proliferative cells in PV and IMF [97]. In ET
(according to the PVSG criteria) myelofibrosis is a delayed
event with a cumulative risk of occurrence estimated at
3% after 5 years, 8% after 10 years and 15% after 15 years
[98]. No clear predictive factor of the risk in patients diag-
nosed according to the PVSG criteria has been published.
According to the WHO classification based on BM biopsy
findings, the risk of fibrotic progression has been esti-
mated to 50% after a median follow-up of 38+/-30
months in IMF-0 or IMF-1 patients. In the description of
IMF-0 and IMF-1, the degree of megakaryocyte dysplasia
and the level of granulocyte hyperplasia are important fea-
tures and may confirm their role in the risk of fibrotic pro-
gression. Fibrotic progression might rarely and even never
be observed in true ET patients [22,48]. In fact, this point
needs confirmation coming from long term prospective
studies.
The status of the JAK2 mutation, however, was not corre-
lated with the presence of fibrosis in ET patients included
in the large prospective MRC PT1 study. In PV patients,
although the role of JAK2 V617F mutation in progression
toward fibrosis is currently unknown, transition from het-Orphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
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erozygoty to homozygoty for JAK2  may represent an
important step in the progression toward post-PV mye-
lofibrosis [49].
• Progression to acute leukemia
In the published literature (concerning often small series
of ET patients with different lengths of follow-up), the risk
of progression to acute leukemia or myelodyplasia during
follow-up ranges from 0.6 to 6.1% [99]. Progression to
acute leukemia represents the most serious life-threaten-
ing complication of ET but is always a late occurring event,
with a median delay of occurrence of 6.5 years [99-101].
The predicting factors of leukemic progression risk
include cytogenetic abnormalities, previous progression
to myelofibrosis or treatment by cytotoxic agent(s) [101].
Untreated patients can transform, but only very rarely,
into acute leukemia [99]. A retrospective study of 2316
Italians suggested an incidence of approximately 1%
[102]. Patients who received previous therapy with P32 or
alkylating agents, or who require more than one cytotoxic
agent, have an increased risk of acute myeloid leukemia
(AML)/MDS [100-105]. It is not clear whether this reflects
the combined effect of the drugs (including HU, which is
the most frequently used drug) or the selection (through
the necessity of more aggressive treatment modalities) of
more evolved and, hence, more progressive forms of the
disease.
However, the leukemogenic potential of HU used alone is
still a matter of controversy. Prospective randomized stud-
ies in ET patients [63,104,105] did not find significant dif-
ference in the incidence of acute leukemia between
untreated patients, or patients treated by HU or anagrelide
alone. However, randomized studies either lack of the
long term follow-up (necessary to evaluate the late toxic-
ity of HU) or were conducted according to the PVSG crite-
ria (ignoring the distinction between IMF-0 and IMF-1
and true ET). According to the WHO classification, IMF-0
and IMF-1 are, in fact, early IMF with a higher propensy to
leukemic transformation than the true ET. In a large retro-
spective study of 357 ET patients treated with HU (most
of them unbiopsied), progression to AML/MDS was
observed in 4.5%, frequently associated with deletion of
17p [101]. In the same study (201 ET patients who had
been treated only with HU) the rate of progression to
AML/MDS was 3.5%. Nielsen and Hasselbalch [106]
reported progression to AML/MDS in about 3.4% in HU-
treated ET patients. The most relevant information of
leukemogenicity of HU is expected to come from prospec-
tive randomized studies of patients classified according to
the WHO guidelines.
Information about the risk of progression to leukemia
and the JAK2 mutation status of ET patients is still limited.
No correlation has been demonstrated. Moreover, the
study of blast cells in two JAK2 mutated ET patients with
acute leukemia failed to demonstrate the JAK2 mutation
in one of them [107].
Unresolved question
Implication of the description of JAK2 V617F mutation on 
the management of ET
Data on the JAK2 mutation status of ET patients cannot, at
present, be used for prognosis assessment. Correlations
between the JAK2 status and the vascular risk and eventu-
ality of clonal progression remain to be established. For
the same reasons, a therapeutic approach based on the
JAK2 positive or negative status of an individual patient
has presently no clinical relevance. However, future pro-
spective studies regarding the treatment of ET must
include a quantitative approach of JAK2 V617F expression
as well as a sophisticated interpretation of the bone mar-
row findings.
Relevance of therapeutic strategies aiming at reduction or 
eradication of the clonal disorder
Allogeneic bone marrow transplantation is exclusively
discussed for those patients who have transformed into
acute leukemia or myelodyplasia or have progressed into
high risk myelofibrosis. Even in this context, transplanta-
tion should be regarded as experimental therapy [108]. At
variance with the model proposed in CML, where a con-
trol of the BCR/ABL positive clone is now the goal of treat-
ment, data concerning the incidence of a similar
therapeutic approach in ET are lacking. The expected
availability of new tyrosine kinase inhibitors may offer
opportunities to test this strategy.
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Polycythemia VeraOrphanet Journal of Rare Diseases 2007, 2:3 http://www.OJRD.com/content/2/1/3
Page 14 of 17
(page number not for citation purposes)
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EPO = Erythropoietin
ET = Essential thrombocythemia
Hb = Hemoglobin
Ht = Hematocrit
HU = Hydroxyurea
INF = Interferon-α
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LMWH = Low molecular weight heparin
MDS = Myelodysplastic syndrome
MPD = Myeloproliferative disorder
MPL = Thrombopoietin receptor
MRC PT1 = Medical Research Council PT1 study
NF-E2 (Nuclear factor erythroid 2)
PCR = Polymerase chain reaction
PI = Pipobroman
PRV-1 = Polycythemia rubra vera protein 1
PT = Primary thrombocythemia
PV = Polycythemia vera
PVSG = Polycythemia Vera Study Group
RhT = Secondary thrombocytoses
Rth = Reactive thrombocytoses
SE = Secondary erythrocytosis
TPO = Thrombopoietin
TRCV = Total red cell volume
VWF = Von Willebrand factor
WBC = White blood bell
WHO = World Health Organization
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